AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12584692
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg via 15-minute infusion)
Trial: 9652613
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine (excluding participants with colds)
Trial: 15383193
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg 3 times daily)
Trial: 2111669
Drug: Intravenous Flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Flecainide acetate (1.5 mg/kg over 5 minutes) - Group I
Trial: 2111669
Drug: Intravenous Flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Flecainide acetate (2 mg/kg over 5 minutes) - Group II
Trial: 359779
Drug: Intramuscular oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular oxycodone
Trial: 359779
Drug: Intramuscular codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular codeine
Trial: 31232275
Drug: Umeclidinium (UMEC)
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium (UMEC) 62.5 µg once-daily added to fluticasone furoate/vilanterol (FF/VI) 200/25 µg once-daily
Trial: 21684715
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of autologous tissue repair cells (TRCs)
Trial: 18332170
Drug: Amoxicillin sprinkle
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin sprinkle (475 mg for ages 6 months to 4 years, 775 mg for ages 5 to 12 years) QD for 7 days
Trial: 18332170
Drug: Penicillin VK
RxNorm normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin VK (10 mg/kg QID for 10 days, max 250 mg QID)
Trial: 16823726
Drug: Vildagliptin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (25 mg, bid)
Trial: 10994155
Drug: Trimebutine tablets
RxNorm normalized name: trimebutine
DrugBank: Trimebutine (DB09089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine tablets (100 mg)
Trial: 10994155
Drug: New tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New tablet formulation (Eurogalena, 100 mg)
Trial: 8466376
Drug: Indwelling Teflon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indwelling Teflon catheter for heparin administration
Trial: 8466376
Drug: Twice-daily subcutaneous
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily subcutaneous injections of heparin
Trial: 24781223
Drug: EEG-BFB-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG-BFB-therapy
Trial: 14748998
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) plus cyclophosphamide (CPA) intermittent intravenous pulse therapy (Group A)
Trial: 10744208
Drug: Injection speed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection speed of 20 seconds (group A)
Trial: 10744208
Drug: Injection speed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection speed of 60 seconds (group B)
Trial: 3304518
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment only (Control)
Trial: 29697830
Drug: Metformin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin with or without rosiglitazone, metformin plus lifestyle
Trial: 22615787
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (bilateral BL2, GB14, TE 23, Ex1, ST1, GB20, LI4, LI11 and single GV23)
Trial: 20839418
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids (mometasone furoate) applied twice daily
Trial: 20839418
Drug: Intralesional steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroids (triamcinolone acetonide) injected at monthly intervals (1 to 2 mg/kg)
Trial: 20839418
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids (mometasone furoate)
Trial: 20839418
Drug: Intralesional steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroids (triamcinolone acetonide)
Trial: 18257978
Drug: Indiplon 5
RxNorm normalized name: Indiplon
DrugBank: Indiplon (DB12590)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indiplon 5 mg
Trial: 2725453
Drug: Zopiclone 3.75
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 3.75 mg
Trial: 2288825
Drug: Midazolam 15
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 15 mg p.o.
Trial: 2288825
Drug: Nitrazepam 5
RxNorm normalized name: nitrazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam 5 mg p.o.
Trial: 6250699
Drug: Nabilone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (2 mg every 12 hours)
Trial: 6250699
Drug: Prochlorperazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (10 mg every 12 hours)
Trial: 23599623
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of normal saline and hydroxyethyl starch (HES) (SH group)
Trial: 23599623
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of normal saline, hydroxyethyl starch and glutamine (SHG group)
Trial: 11419611
Drug: Relaxation Response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Relaxation Response Meditation (twice a day for 15 minutes for six weeks)
Trial: 8275619
Drug: Diazepam 40
RxNorm normalized name: Diazepam 400 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 40 mg
Trial: 8275619
Drug: Pentobarbital 120
RxNorm normalized name: PENTobarbital 120 mg rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital 120 mg
Trial: 8275619
Drug: Pentobarbital 240
RxNorm normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentobarbital 240 mg
Trial: 27004531
Drug: Carbetocin 100
RxNorm normalized name: Carbetocin 100 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 100 mcg as a slow intravenous bolus
Trial: 27004531
Drug: Carbetocin 100
RxNorm normalized name: Carbetocin 100 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 100 mcg as a short-infusion in 100 ml 0.9% sodium chloride
Trial: 23511711
Drug: Midazolam (0.0001‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.0001‐3 mg)
Trial: 20107296
Drug: Desvenlafaxine succinate
RxNorm normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine succinate (DVS) 50 mg/day
Trial: 20107296
Drug: Desvenlafaxine succinate
RxNorm normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine succinate (DVS) > 50 mg/day
Trial: 20107296
Drug: Desvenlafaxine succinate
RxNorm normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine succinate (DVS) 50-100 mg/day
Trial: 16246442
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (2 g) administration
Trial: 16246442
Drug: No ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No ascorbic acid administration (control)
Trial: 18388877
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg gemfibrozil
Trial: 12687332
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg itraconazole (first dose 200 mg)
Trial: 12687332
Drug: gemfibrozil alone
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gemfibrozil alone and in combination with itraconazole
Trial: 10588314
Drug: Valacyclovir 1000
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 1000 mg once daily
Trial: 21106086
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg twice daily
Trial: 1656713
Drug: ARI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARI treatment (sorbinil)
Trial: 31857319
Drug: Biomarker (AR-V7)
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker (AR-V7) guided clinical treatment
Trial: 27120420
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy for Health Anxiety (CBT-HA)
Trial: 25417405
Drug: Xinmailong injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinmailong injection
Trial: 22458917
Drug: DDS‐06C (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDS‐06C (75 mg tramadol/650 mg paracetamol)
Trial: 18628467
Drug: Poxvirus-based PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poxvirus-based PSA vaccine
Trial: 18628467
Drug: Vaccine followed
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine followed by Nilutamide
Trial: 18628467
Drug: Nilutamide followed
RxNorm normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilutamide followed by Vaccine
Trial: 18628467
Drug: Vaccine arm
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine arm (Gleason score <7)
Trial: 18628467
Drug: Vaccine arm
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine arm (PSA <20 ng/dL)
Trial: 18628467
Drug: Vaccine arm
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine arm (prior radiation therapy)
Trial: 8018638
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of mifepristone and Placebo
Trial: 30320503
Drug: Oral Antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Antidiabetic Drugs (OAD)
Trial: 15677608
Drug: Selegiline augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline augmentation of antipsychotic medication
Trial: 13679527
Drug: High-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity warfarin (INR 3.1 to 4.0)
Trial: 13679527
Drug: Moderate-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity warfarin (INR 2.0 to 3.0)
Trial: 15869575
Drug: High-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity warfarin
Trial: 13679527
Drug: Moderate-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity warfarin
Trial: 8122946
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg lovastatin
Trial: 7957469
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow immunoscintigraphy using a 99mTc‐labelled anti‐NCA‐95 monoclonal antibody
Trial: 2887726
Drug: Yohimbine (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (18 mg a day)
Trial: 30922733
Drug: Capecitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1250 mg/m2 twice daily on days 1–14 of a 21-day cycle, for eight cycles)
Trial: 28554599
Drug: CAM2038 q1w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM2038 q1w (7.5, 15, 22.5, and 30mg doses)
Trial: 15554568
Drug: Methylphenidate (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (titrated from 0.5 mg/kg per day in week 1 to 1.0 mg/kg per day in week 3)
Trial: 11483834
Drug: Intranasal influenza
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal influenza vaccine (1 or 2 doses)
Trial: 11483834
Drug: Intranasal influenza
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal influenza vaccine
Trial: 9663731
Drug: Psyllium (5.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (5.1 g b.d.)
Trial: 9663731
Drug: Docusate sodium
RxNorm normalized name: Docusate Sodium
DrugBank: Docusate (DB11089)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docusate sodium (100 mg b.d.)
Trial: 8164599
Drug: Antacid (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (40 mmol/day)
Trial: 3257375
Drug: Cefamandole 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole 15 mg/kg administered intravenously shortly before cannulation (Group 2)
Trial: 3257375
Drug: Cefamandole 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole 30 mg/kg administered intravenously during induction of anesthesia (Group 1)
Trial: 31748467
Drug: 420 mg
RxNorm normalized name: choline 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 mg evolocumab every 4 weeks (Q4W)
Trial: 31748467
Drug: 140 mg
RxNorm normalized name: caffeine 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg evolocumab every 2 weeks (Q2W)
Trial: 31748467
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ezetimibe daily
Trial: 30972995
Drug: CSII combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII combined with sitagliptin treatment (group C)
Trial: 30972995
Drug: CSII combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII combined with acarbose treatment (group B)
Trial: 30972995
Drug: CSII treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII treatment alone (group A)
Trial: 28355090
Drug: TX-004HR (4-μg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX-004HR (4-μg, 10-μg, and 25-μg doses)
Trial: 26344671
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) treatment, intravenous, open-label, assessed over the first 4 months (5 infusions).
Trial: 21761206
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron 30 min before spinal anesthesia (group II; n=150)
Trial: 21761206
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment groups (II, III)
Trial: 14966631
Drug: Metronidazole-chlorhexidine solution
RxNorm normalized name: chlorhexidine / metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole-chlorhexidine solution
Trial: 8384186
Drug: ephedrine/caffeine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ephedrine/caffeine combination (20mg/200mg)
Trial: 1318281
Drug: ephedrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ephedrine (20 mg)
Trial: 1318281
Drug: caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: caffeine (200 mg)
Trial: 31331803
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery applied perioperatively (once preoperatively, once on the first postoperative day, twice on the second and third days, totaling six applications)
Trial: 31331803
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment and nursing care
Trial: 29870922
Drug: Capacitive-resistive electric
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capacitive-resistive electric transfer therapy (Tecar)
Trial: 25130297
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg IV for 5 days
Trial: 25130297
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg IV for 7-14 days
Trial: 15899100
Drug: Lumiracoxib 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 100 mg od
Trial: 15899100
Drug: Lumiracoxib 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 100 mg od with loading dose of 200 mg od for the first two weeks
Trial: 15899100
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg od
Trial: 10086760
Drug: Collaborative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative treatment by primary care physicians (PCPs) and mental health providers (MHPs)
Trial: 383417
Drug: PEEP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEEP therapy (10 patients)
Trial: 24720268
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia
Trial: 26140739
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg/dL)
Trial: 21134995
Drug: Simvastatin therapy
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin therapy (20 mg/day, group Ia, n = 15)
Trial: 21134995
Drug: Hypolipidemic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypolipidemic diet therapy (group Ib, n = 15)
Trial: 19034106
Drug: Tariquidar (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tariquidar (150 mg)
Trial: 16310974
Drug: Post-treatment motivation
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment motivation
Trial: 1590680
Drug: Cefprozil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil (500 mg every 12 h for 8 days)
Trial: 3844036
Drug: Repeated 3-g
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated 3-g doses of amoxycillin
Trial: 3844036
Drug: Single 3-g
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 3-g dose of amoxycillin
Trial: 30706097
Drug: Methylphenidate (MPH,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH, 20 mg)
Trial: 30264159
Drug: Loading doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading doses of atorvastatin (80 mg) administered before and 24 hours after PCI.
Trial: 30264159
Drug: Loading doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading doses of atorvastatin (80 mg) administered less than 12 hours before PCI.
Trial: 30264159
Drug: Loading doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading doses of atorvastatin (80 mg) in patients with ST-segment elevation myocardial infarction (STEMI).
Trial: 30264159
Drug: Loading doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading doses of atorvastatin (80 mg) in patients with non-ST-segment elevation ACS.
Trial: 23735746
Drug: Golimumab 200
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab 200 mg/100 mg
Trial: 23735746
Drug: Golimumab 400
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab 400 mg/200 mg
Trial: 23521375
Drug: Single-dose nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose nevirapine (sdNVP)
Trial: 18614871
Drug: Combination ZDV/sdNVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ZDV/sdNVP
Trial: 18614871
Drug: Short-course highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course highly active antiretroviral therapy (HAART)
Trial: 6345428
Drug: Flurbiprofen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (300 mg daily)
Trial: 6345428
Drug: Diclofenac (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (200 mg daily)
Trial: 30272850
Drug: Individualised nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised nutrition education with customised dishware and food supplements (mixed nuts and skimmed milk powder)
Trial: 30272850
Drug: Multiple micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrients plus isolated soy protein supplement